MSH3 is altered in 2.37% of malignant solid tumor patients [3].

MSH3 is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain MSH3 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

MSH3 is altered in 2.13% of prostate adenocarcinoma patients [3].

MSH3 is an inclusion criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain MSH3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].

MSH3 is altered in 2.1% of prostate carcinoma patients [3].

MSH3 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MSH3 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

MSH3 is altered in 0.94% of breast carcinoma patients [3].

MSH3 is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MSH3 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [4].

MSH3 is altered in 0.52% of ovarian carcinoma patients [3].

MSH3 is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MSH3 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

MSH3 is altered in 6.67% of colorectal carcinoma patients [3].

MSH3 is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH3 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

MSH3 is altered in 1.04% of cervical carcinoma patients [3].

MSH3 is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

MSH3 is altered in 3.08% of adenocarcinoma of the gastroesophageal junction patients [3].

MSH3 is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain MSH3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

MSH3 is altered in 1.36% of non-small cell lung carcinoma patients [3].

MSH3 is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MSH3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

MSH3 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MSH3 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 7.32% of endometrial carcinoma patients [3].

MSH3 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 1.52% of head and neck squamous cell carcinoma patients [3].

MSH3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

MSH3 is altered in 1.06% of soft tissue sarcoma patients [3].

MSH3 is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

MSH3 is altered in 0.62% of pancreatic carcinoma patients [3].

MSH3 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MSH3 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MSH3 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

MSH3 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

MSH3 is altered in 6.48% of gastric adenocarcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 6.46% of gastric carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH3 is altered in 6.46% of malignant gastric neoplasm patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 6.59% of malignant intestinal neoplasm patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 3.86% of melanoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 5.56% of malignant uterine neoplasm patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 2.94% of ampulla of vater carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 3.65% of malignant esophagogastric neoplasm patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 4.44% of malignant small intestinal neoplasm patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 2.37% of bladder urothelial carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 2.19% of bladder carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 2.65% of gallbladder carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 2.38% of urothelial carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 1.36% of head and neck carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 1.36% of lung carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 1.4% of small cell lung carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 0.66% of malignant ovarian epithelial tumor patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 0.99% of bile duct carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 0.99% of cholangiocarcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 0.63% of pancreatic adenocarcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is altered in 0.37% of esophageal carcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 0.31% of gastrointestinal stromal tumor patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MSH3 is altered in 0.41% of high grade ovarian serous adenocarcinoma patients [3].

MSH3 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MSH3 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MSH3 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].